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Case report
A 72-year-old Caucasian male underwent wide local ex-
cision of  an ulcerated, 1.4-mm Breslow thickness, Clark 
level IV, articular melanoma in 2004. There was no evi-
dence of  regression, lymphovascular invasion, perinodal 
extension, or microsatellitosis at diagnosis. The surgical 
margins were clear, and the sentinel lymph node biopsy 
revealed no evidence for additional disease. His initial stage 
was therefore IIA (T2b, N0, M0). In the fall of  2007, FDG 
PET/CT showed multiple small pulmonary nodules, with 
maximum SUV (SUVmax) of  3.8 g/ml. CT-guided needle 
biopsy of  one nodule revealed metastatic melanoma. The 
patient completed two cycles on a clinical trial of  VEGF-
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We describe a patient with metastatic melanoma, one year following a clinical trial of  VEGF Trap anti-
angiogenic therapy, in whom a restaging whole-body FDG PET/CT demonstrated a new, intensely 
FDG-avid, intra-articular soft-tissue mass in the left knee (SUV=25 g/ml). MRI revealed findings com-
patible with nodular pigmented villonodular synovitis (PVNS), also known as giant-cell tumor of  the 
tendon sheath (GCTTS), which was confirmed by excisional biopsy. Increased FDG uptake within teno-
synovial giant-cell tumors can be explained on the basis of  their high monocyte/macrophage content. 
Radiologists must be aware that both melanoma and tenosynovial giant-cell tumors can be intensely 
FDG-avid, in order to avoid a false-positive interpretation.
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Figure 1A. 72-year-old man with giant-cell tumor of the ten-
don sheath. FDG PET/CT. Attenuation-corrected, maximum-
intensity projection FDG PET shows intense FDG uptake 
within the lateral compartment of the right knee.
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Figure 1B. 72-year-old man with giant-
cell tumor of the tendon sheath. FDG 
PET/CT. Bone-windowed transaxial 
image from the noncontrast CT com-
ponent shows a solid, soft-tissue-
density, intra-articular mass, centered 
at the synovium.
Figure 1C. 72-year-old man with giant-
cell tumor of the tendon sheath. FDG 
PET/CT. Soft-tissue-windowed, tran-
saxial fused PET/CT image shows in-
tense FDG uptake within the mass. 
Maximum SUV was 25 g/ml.
Figure 2. 72-year-old man with giant-cell tumor of the tendon sheath. MR 
imaging shows findings typical of intra-articular GCTTS (PVNS). Left: Sagittal 
T1 weighted image shows low signal. Right: Proton density with fat saturation 
shows intermediate signal.
Figure 2. 72-year-old man with giant-cell tumor of the tendon sheath. MR 
imaging shows findings typical of intra-articular GCTTS (PVNS). Left. Sagittal 
T1-weighted imaging with fat saturation, post-IV-gadolinium, shows en-
hancement within the mass. RIght. Corresponding sagittal-fused FDG PET/
CT image demonstrates intense FDG uptake, with SUVmax 25 g/ml.
Figure 2. 72-year-old man with giant-cell tumor of the tendon sheath. MRI 
shows findings typical of intra-articular GCTTS (PVNS). Left. Transaxial MR 
inversion recovery. Right. T1-weighted fat saturation imaging postgadolinium.
Trap, a novel anti-angiogenesis type therapeutic agent, but 
had to discontinue therapy in January 2008 because he 
developed grade IV hypertension as a side effect. His dis-
ease remained stable off  therapy until April 2009, when a 
followup noncontrast FDG PET/CT scan revealed an in-
tensely hypermetabolic intra-articular soft-tissue-density 
lesion in the left knee (SUVmax = 25 g/ml); this was 
thought to be highly suspicious for metastatic melanoma 
(Fig. 1), although no prior imaging of  the knee was avail-
able to establish the chronicity of  the finding.
Further investigation with MRI revealed a 2.4 x 1.4 x 
2.0-cm lesion within Hoffa’s fat pad, demonstrating inter-
mediate T1 signal, heterogeneous low-to-intermediate T2 
signal, and heterogeneous contrast enhancement (Fig. 2).
These MRI findings are typical of  GCTTS (PVNS), but 
metastatic melanoma could not be entirely excluded based 
on MRI. Surgical resection revealed an ovoid, encapsulated 
mass measuring 2.5 x 2.0 x 1.2 cm, with a smooth pink-tan 
outer surface and a variegated yellow-tan-brown cut sur-
face. Histopathology revealed histiocyte-like tumor cells, 
lymphocytes, hemosiderin-laden macrophages, and 
osteoclast-like giant cells, consistent with localized GTTTS 
(PVNS). Immunostaining with HMB-45 was negative, thus 
ruling out metastatic melanoma (Fig. 3).
Discussion
GCTTS (PVNS) is a benign neoplasm that develops in 
the synovium of  joints, tendon sheaths, and bursae. This 
tumor has a chromosomal translocation, t(1:2)(p13;q37), 
which results in overexpression of  CSF1, a chemoattractant 
for macrophages. Histiocytic cells of  the monocyte/
macrophage cell line constitute the majority of  cells in 
these tumors at biopsy, whereas the polyhedral neoplastic 
cells account for only 2% to 16% of  total cells. The macro-
phages contain hemosiderin- and lipid-laden vacuoles, and 
thus can be mistaken for melanoma cells when viewed 
through the microscope. Immunostaining of  GCTTS 
(PVNS) with HMB-45, a human monoclonal antibody that 
binds specifically to an antigen expressed by melanocytic 
tumors, is negative.
Current literature specifically addressing FDG avidity of  
tenosynovial giant-cell tumors is sparse. Watanabe, et al., in 
a series of  55 patients with musculoskeletal tumors, de-
scribe one GCTTS in the knee of  a 28-year-old woman, 
with the lesion measuring 3 x 4 x 4 cm, and having 
SUVmax = 4.4 g/ml (1). Wissmeyer, et al. reported a 2.8 x 
4.5-cm GCTTS in the hip of  a 70-year-old man, with 
SUVmax = 5.8 g/ml (2). Adler, et al., in a series of  25 pa-
tients with mass lesions involving the musculoskeletal sys-
tem, reported two cases of  PVNS, one of  which was in-
traosseous, with average FDG DUR (dose/uptake ratio) of  
0.65 and 0.31, but SUVmax for these lesions was not re-
ported (3). Aoki et al., in a series of  114 soft-tissue masses, 
reported five GCTTS with SUVmax = 5.06 +/- 1.63 g/ml 
(4). A case of  PVNS, with SUV = 11.3, was reported by 
Kitapci and Coleman (5). We know of  no published cases 
of  FDG imaging of  tenosynovial giant-cell tumors demon-
strating SUVmax in the range of  25 g/ml, or greater than 
11.3 g/ml.
The intense FDG avidity of  malignant melanoma, on the 
other hand, is well documented. Although sentinel lymph-
node biopsy is the gold standard for detection of  microme-
tastases to regional lymph nodes, FDG PET/CT is widely 
known to be highly accurate in predicting both residual/
recurrent melanoma and distant metastases (6, 7, 8, 9). In 
general, the likelihood of  a lesion to represent malignant 
melanoma increases with increasing SUVmax.
Cellular uptake of  FDG in human tumor cells has re-
cently been linked to the expression of  glucose transporter 
protein GLUT-1, hexokinase II, and to the upregulation of  
genes for production of  these proteins. Ong et al., found 
significantly higher amounts of  GLUT-1 and hexokinase II 
in five different human cancer cell lines (as compared to 
normal cells) using Western blot analysis, and they demon-
strated strong correlations between cellular expression of  
GLUT-1, expression of  hexokinase II, in vitro histological 
FDG uptake assays, and FDG SUVmax (determined by in 
vivo microPET imaging of  intrahepatic tumor models us-
ing SCID mice (10]). Hamada et al., in a series of  49 pa-
tients with musculoskeletal tumors, showed a positive corre-
lation of  FDG SUVmax with the expression of  GLUT-1 
and hexokinase II (11). Several investigators have previously 
demonstrated upregulation of  GLUT-1 in human 
monocyte-derived macrophages (12, 13, 14). From studies 
such as these, we infer that FDG avidity within tenosynovial 
giant-cell tumors may be explained on the basis of  their 
high monocyte/macrophage content. Of  note, granuloma-
tous lesions containing active macrophages are widely rec-
FDG uptake in an intra-articular localized giant-cell tumor (PVNS) mimics metastatic melanoma
RCR Radiology Case Reports | radiology.casereports.net! 3! 2009 | Volume 4 | Issue 4  
Figure 3. 72-year-old man with giant-cell tumor of the ten-
don sheath. High-power view (20X) shows histiocyte-like 
tumor cells, lymphocytes, hemosiderin-laden macrophages 
and osteoclast-like giant cells consistent with localized 
GTTTS (PVNS). 
ognized as being causes of  false-positive interpretations of  
FDG PET in oncology. Radiologists and Nuclear Medicine 
Physicians should be aware that both melanomas and 
GCTTS (PVNS) can be intensely FDG-avid, and that teno-
synovial tumors should be included in the differential diag-
nosis of  intensely FDG-avid neoplasms located within 
synovial joints, tendon sheaths, or bursae.
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